Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025)

Silence Therapeutics' (SLN) quarterly Cash from Financing Activities came in at $1000.0 in Q2 2025, down 99.92% year-on-year from $1.2 million in Q2 2024, and down 92.86% quarter-over-quarter from $14000.0 in Q1 2025.

Silence Therapeutics (SLN) Cash from Financing Activities (2024 - 2025) Analysis & Trends

Silence Therapeutics has disclosed Cash from Financing Activities across 2 years of filings, most recently posting $1000.0 for Q2 2025.

  • Cash from Financing Activities for Q2 2025 came in at $1000.0, down 99.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $1000.0 (down 99.99% YoY), and the FY2025 annual result was $15000.0, down 99.99% from the prior year.
  • Cash from Financing Activities came in at $1000.0 for Q2 2025 at Silence Therapeutics, down from $14000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $133.0 million in Q1 2024 to a low of -$98000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 7.00 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -600,000.00
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 53,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -538.80 Mn
9 Abivax 91.96 Bn 91.96 Bn - 85,464.43
10 Silence Therapeutics 966.41 Mn 896.33 Mn 411,000.00 -

Historic Data

Download Data
DateValue
Jun 30, 2025 1,000.00
Jun 30, 2025 1,000.00
Mar 31, 2025 14,000.00
Mar 31, 2025 14,000.00
Dec 31, 2024 -98,000.00
Dec 31, 2024 -98,000.00
Sep 30, 2024 7.97 Mn
Sep 30, 2024 7.97 Mn
Jun 30, 2024 1.19 Mn
Jun 30, 2024 1.19 Mn
Mar 31, 2024 133.02 Mn
Mar 31, 2024 133.02 Mn